Medical Xpress

FEBRUARY 22, 2023

Medicines that are based on mRNAs and proteins—particularly vaccines and antibodies—are time-intensive and costly to make. The challenge is in producing the necessary mRNAs and proteins in large enough amounts at low cost.

Protein 75

Protein Medicine Production Antibody 75

Pharmaceutical Technology

NOVEMBER 14, 2022

The antibody-drug conjugate (ADC) treatment is indicated for such patients who have previously received one to three systemic therapy regimens, irrespective of the usage of Avastin priorly. binding antibody, a cell-surface protein which is greatly expressed in ovarian cancer, as well as the maytansinoid payload DM4.

Antibody 246

Antibody FDA Approval Clinical Trials Clinical Trials 246

pharmaphorum

JULY 27, 2022

Pfizer and BioNTech have started a mid-stage trial of a new version of the COVID-19 vaccine based on a version of the spike protein that they hope will offer greater and broader protection against SARS-CoV-2 variants. Clinical data show strong neutralising antibody responses against Omicron BA.1,

Protein 122

Protein Immune Response Vaccination Vaccine 122

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. According to the study, patients had auto-antibodies against IFN-? (13 We said, ‘bingo!’”

Antibody 135

Antibody Genetics Research In-Vitro 135

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie has begun a phase 1 clinical trial of the antibody, with clinical development beginning in the US and expanding into Europe.

Antibody 98

Antibody Trials Licensing Licensing 98

Medical Xpress

JANUARY 4, 2023

The researchers found no differences in antibody production, auto-antibodies, T cell profiles, or prior viral exposures, but found elevated levels of spike protein along with increased cytokines (consistent with innate inflammation) and increased troponin (indicating cardiac injury).

Immune Response 96

Immune Response Protein Vaccine Vaccination 96

Pharmaceutical Technology

FEBRUARY 3, 2023

Additionally, advances in the study of broadly neutralising antibodies (bNAbs) have led to new candidates being studied in early trials. While the production of bNAbs is a complicated process, vaccines could be designed to prompt the body to induce bNAbs, says Karim. This response was also seen in the RV 144 trial, she notes.

Vaccine 293

Vaccine Vaccination Antibody Trials 293

Camargo

NOVEMBER 29, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. Definition of Biologic Products. These products can be derived from humans, animals, or microorganisms with biotechnology.

Development 180

Development Protein Production Hormones 180

Pharmaceutical Technology

FEBRUARY 22, 2023

The patent battle between Amgen and Sanofi over their cholesterol-lowering antibodies has divided big pharma in the past months. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. But in this case, Amgen has a fully finished product, he adds. Amgen’s Repatha was greenlit a month later.

Antibody 262

Antibody Drugs Protein Sales 262

XTalks

MARCH 31, 2023

By growing high quality crystal structures of protein-based therapeutics under microgravity, researchers can gain better insights into their complex structures and stability. The proteins will be analyzed back on Earth using techniques such as X-ray diffraction and compared with crystals from the same biologics grown on Earth.

Protein 97

Protein Research Development Manufacturing 97

Pharmaceutical Technology

JANUARY 16, 2023

Ono Pharmaceutical and Monash University have entered an option and research collaboration for the discovery and development of antibodies that target G protein-coupled receptors (GPCRs).

Research 130

Research Antibody Sales Development 130

pharmaphorum

AUGUST 25, 2021

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 Lilly has bought into Lycia’s lysosomal targeting chimera (LYTAC) protein degradation technology, developed by Bertozzi at Stanford University, with an initial focus on projects in immunological disease and pain.

Protein 69

Protein Licensing Licensing Drugs 69

Pharmaceutical Technology

MARCH 10, 2023

Freeze drying is a crucial technique to prolong the shelf life of pharmaceutical products. Also known as lyophilisation, the technique stabilises and preserves sensitive products such as biologics, and diagnostic kits, in a permanently storable state. The process eliminates the disadvantages of conventional drying methods or freezing.

Manufacturing 147

Manufacturing Production Containment Antibody 147

XTalks

FEBRUARY 29, 2024

Dual-function fusion proteins represent a cutting-edge approach in biopharmaceutical research, offering a promising avenue for the development of novel therapeutics in the treatment of complex diseases such as cancer and autoimmune disorders. At the helm of this venture is Dr. Taylor H. How is your lead program differentiated?

Protein 94

Protein Development Clinical Trials Clinical Trials 94

BioPharma Reporter

MARCH 8, 2022

Flow Eighteen38, a protein sciences division created to facilitate and accelerate antibody characterization and protein purification projects, has announced a â5m ($5.58m) investment into its protein production and biophysical characterization capabilities and services from its parent company, CRO FairJourney Biologics S.A.

Protein 52

Protein Antibody Production 52

Pharmaceutical Technology

APRIL 13, 2023

Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.

Medicine 130

Medicine Development Antibody Engineer 130

pharmaphorum

FEBRUARY 14, 2022

A recent report has found that R&D productivity rose vertiginously during 2021, but how much of this was organic and how much can be attributed to the pandemic? The pandemic also saw a reduction in the overall development cycle of a product, which has been growing in recent years. In 2020, the development cycle averaged 7.14

Production 98

Production Clinical Trials Clinical Trials Sales 98

Pharmaceutical Technology

SEPTEMBER 7, 2022

Biopharma companies are under pressure to do more with less in the production of monoclonal antibody (mAb) therapies. However, these processes can damage cells, resulting in more impurities in the downstream process to remove and decreasing the product quality. The first is to increase the specific productivity of the cells.

Protein 130

Protein Production DNA Manufacturing 130

Pharmaceutical Technology

FEBRUARY 1, 2023

Since the FDA approved AstraZeneca’s monoclonal antibody therapy Synagis (palivizumab) 25 years ago, drug development successes for RSV have been few and far between. In 2013, this changed when an NIH lab reported the structure of the RSV protein, leading to the exploration of the RSV structure in ways that were not previously possible.

Vaccine 162

Vaccine Vaccination Antibody Development 162

Pharmaceutical Technology

MAY 9, 2023

FibroGen has signed an exclusive licence agreement with Fortis Therapeutics for the FOR46 antibody-drug conjugate (ADC) that targets a new epitope on CD46, a protein-coding gene. FOR46 is currently being investigated in a Phase I trial as a potential treatment for metastatic castration-resistant prostate cancer (mCRPC).

Drugs 130

Drugs Clinical Development Antibody Protein 130

Pharmaceutical Technology

JUNE 4, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Gene 262

Gene Gene Therapy Genetics DNA 262

Pharmaceutical Technology

JUNE 8, 2023

These solutions will help drug developers address the challenges of regulatory compliance, production scalability, quality assurance and cost-effectiveness. The new CGTs treat a broad range of indications including rare diseases, immune disorders and blood cancers.

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

Scienmag

MAY 26, 2021

A […].

Immune Response 54

Immune Response Protein Vaccine Vaccination 54

Pharmaceutical Technology

APRIL 18, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Protein 147

Protein Vaccination Vaccine Production 147

Roots Analysis

SEPTEMBER 9, 2024

Over the years, pharmaceutical companies have shifted their priorities from traditional interventions towards more advanced pharmacological strategies, such as protein therapeutics. Further, $400 billion is the anticipated sales of protein-based therapeutics in 2023. The mRNA is then translated into to form functional proteins.

Protein 40

Protein Gene Production DNA 40

The Pharma Data

JANUARY 14, 2021

The FDA has issued straight-to-final guidance that provides sponsors of monoclonal antibody and other therapeutic protein COVID-19 treatments with recommendations for potency assays to ensure consistent product quality. Source link.

Protein 52

Protein Antibody Production Research 52

XTalks

FEBRUARY 8, 2021

While the approval pathway for biosimilar products was established 12 years ago, there are still misconceptions about how biosimilars are approved, biosimilarity versus interchangeable status and which patients can be treated with biosimilars. What is an Interchangeable Biological Product? What is a Biosimilar?

Production 78

Production Insulin Branding Generic Drugs 78

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

RNA 240

RNA Genetics Vaccination Vaccine 240

Pharmaceutical Technology

JANUARY 19, 2023

Nuvaxovid is a protein-based vaccine created from the genetic sequence of the initial SARS-CoV-2 virus strain. Nuvaxovid demonstrated a significant antibody response when given as a booster dose after primary vaccination with other authorised Covid-19 doses in the COV-BOOST trial.

Vaccine 147

Vaccine Vaccination Immune Response Protein 147

Pharmaceutical Technology

SEPTEMBER 13, 2022

The multi-year investment, covering the development of drug substances as well as drug products, will be implemented across the current locations of the company in Switzerland, Austria and Slovenia. For this purpose, the company will create a completely integrated scientific environment.

Antibody 130

Antibody Development Clinical Trials Clinical Trials 130

Pharmaceutical Technology

MAY 17, 2023

The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody. It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

Pharmaceutical Technology

FEBRUARY 19, 2023

It is a monoclonal antibody conjugate that acts by targeting f olate receptor alpha (FolR alpha). The company develops its pipeline products through the Xpress CF and XpressCF+ platform, a biochemical protein synthesis system that develops therapeutic proteins and discovers drugs for the treatment and prevention of diseases.

Antibody 100

Antibody Protein Clinical Development Manufacturing 100

XTalks

APRIL 1, 2025

In hemophilia patients, inhibitors are antibodies that interfere with the effectiveness of clotting factor replacement therapies. Management typically involves on-demand treatment or preventive (prophylactic) therapy using FVIII or FIX replacement products, or agents that mimic the function of these factors.

FDA Approval 59

FDA Approval RNA Clinical Trials Clinical Trials 59

The Pharma Data

OCTOBER 27, 2021

A study conducted by a consortium of Brazilian researchers has demonstrated that a hyperimmune serum consisting of purified antibody fragments produced in horses may be an efficient approach to combat COVID-19. The scientists are confident of the efficiency of the new product. 1 (Gamma) and P.2 2 variants. .

Antibody 52

Antibody Protein Scientist Clinical Trials 52

Pharmaceutical Technology

AUGUST 23, 2022

It comprises messenger ribonucleic acid (mRNA) that encodes for the initial spike protein of SARS-CoV-2 along with mRNA that encodes for Omicron BA.4/BA.5 5 variant spike protein. According to pre-clinical findings, a booster dose of this vaccine elicited a robust neutralising antibody response against the variants Omicron BA.1,

Vaccine 130

Vaccine Vaccination Gene Therapy Protein 130

Pharmaceutical Technology

APRIL 28, 2023

Its scope includes Syngene providing integrated drug discovery and development solutions in discovery chemistry and biology, peptide chemistry, antibody and protein reagents, pharmacokinetics and drug metabolism, and pharmaceutical development. until 2026. Syngene’s collaboration with Zoetis started in 2011.

Manufacturing 130

Manufacturing Antibody Clinical Supply Protein 130

pharmaphorum

JANUARY 7, 2022

NI006 is an antibody that binds to the misfolded forms of the transthyretin protein that form the fibrils, and cause them to be cleared away by immune cells like macrophages. Tafamidis is thought to work by stabilising the misfolded proteins.

Antibody 116

Antibody Licensing Licensing Protein 116